TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

Benzinga Logo Benzinga • •By Vandana Singh
AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

AbbVie reported strong Q3 2025 financial results with $15.78 billion in sales, increased dividend to $1.73 per share, and raised fiscal 2025 earnings guidance to $10.61-$10.65 per share, driven by robust immunology portfolio growth.

Insights
ABBV   positive

Strong sales growth of 9.1%, significant immunology portfolio performance (Skyrizi sales up 46.8%), raised earnings guidance, and increased quarterly dividend indicate robust financial health and strategic momentum